Top section
Top section
Hybrid capital is open to the big US tech companies. But who needs an umbrella when the sun is shining?
Years of underperformance are behind it and the bank has launched a new growth plan
Bond set to be priced at implied vol above secondaries
More articles
More articles
More articles
-
EMEA’s equity capital markets were buzzing on Friday morning after Goldman Sachs placed a 13.2m block of shares in Cellnex, the Spanish telecoms tower company, which allowed the company’s largest shareholder to monetise rights that it intends not to exercise in the issuer's forthcoming €4bn rights issue. -
Ayala Land Real Estate Investment Trust is set to raise Ps12.3bn ($249.9m) from the Philippines' first Reit listing.
-
Indian private sector lender Axis Bank has lined up four European banks for an equity sale that could raise up to Rp150bn ($2bn), according to a source close to the deal.
-
Sino Biopharmaceutical’s chief executive Tse Ping has sold a portion of his stake in the company for the second time this year, pocketing HK$3.15bn ($406.4m) but causing the stock price to tumble in the secondary market.
-
The European Commission is looking to change its rules on research unbundling and other aspects of MiFID II to ease the post-coronavirus recovery in the EU. It is also set to present tweaks to rules on securitization and prospectuses.
-
BioNTech, the German biopharmaceuticals company, is selling 5.5m American Depositary Receipts (ADRs) on the Nasdaq through a share sale and a rights issue. The company, which is working with Pfizer to develop a vaccine for Covid-19, is the latest issuer to hit the market in a wave of biotech ECM issuance — but buyers are being warned against being too eager, reports Sam Kerr.
Sub-sections
shared comment list
